BioAge Labs Statistics
Total Valuation
BioAge Labs has a market cap or net worth of $239.12 million. The enterprise value is -$139.31 million.
| Market Cap | 239.12M |
| Enterprise Value | -139.31M |
Important Dates
The next estimated earnings date is Thursday, November 5, 2026, after market close.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioAge Labs has 45.90 million shares outstanding. The number of shares has increased by 43.29% in one year.
| Current Share Class | 45.90M |
| Shares Outstanding | 45.90M |
| Shares Change (YoY) | +43.29% |
| Shares Change (QoQ) | +5.55% |
| Owned by Insiders (%) | 2.36% |
| Owned by Institutions (%) | 76.92% |
| Float | 39.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 24.51 |
| Forward PS | 83.32 |
| PB Ratio | 0.68 |
| P/TBV Ratio | 0.68 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.19, with a Debt / Equity ratio of 0.01.
| Current Ratio | 17.19 |
| Quick Ratio | 16.75 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -378.19 |
Financial Efficiency
Return on equity (ROE) is -28.21% and return on invested capital (ROIC) is -19.50%.
| Return on Equity (ROE) | -28.21% |
| Return on Assets (ROA) | -18.47% |
| Return on Invested Capital (ROIC) | -19.50% |
| Return on Capital Employed (ROCE) | -28.14% |
| Weighted Average Cost of Capital (WACC) | 10.17% |
| Revenue Per Employee | $167,016 |
| Profits Per Employee | -$1.52M |
| Employee Count | 62 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -10.91% in the last 52 weeks. The beta is 1.08, so BioAge Labs's price volatility has been similar to the market average.
| Beta (5Y) | 1.08 |
| 52-Week Price Change | -10.91% |
| 50-Day Moving Average | 7.87 |
| 200-Day Moving Average | 16.12 |
| Relative Strength Index (RSI) | 30.50 |
| Average Volume (20 Days) | 838,775 |
Short Selling Information
The latest short interest is 3.27 million, so 7.13% of the outstanding shares have been sold short.
| Short Interest | 3.27M |
| Short Previous Month | 3.07M |
| Short % of Shares Out | 7.13% |
| Short % of Float | 8.36% |
| Short Ratio (days to cover) | 4.67 |
Income Statement
In the last 12 months, BioAge Labs had revenue of $10.36 million and -$94.46 million in losses. Loss per share was -$2.37.
| Revenue | 10.36M |
| Gross Profit | -77.43M |
| Operating Income | -106.27M |
| Pretax Income | -94.46M |
| Net Income | -94.46M |
| EBITDA | -106.02M |
| EBIT | -106.27M |
| Loss Per Share | -$2.37 |
Balance Sheet
The company has $318.75 million in cash and $2.84 million in debt, with a net cash position of $378.43 million or $8.25 per share.
| Cash & Cash Equivalents | 318.75M |
| Total Debt | 2.84M |
| Net Cash | 378.43M |
| Net Cash Per Share | $8.25 |
| Equity (Book Value) | 374.91M |
| Book Value Per Share | 8.19 |
| Working Capital | 311.10M |
Cash Flow
In the last 12 months, operating cash flow was -$87.60 million and capital expenditures -$488,000, giving a free cash flow of -$88.09 million.
| Operating Cash Flow | -87.60M |
| Capital Expenditures | -488,000 |
| Depreciation & Amortization | 251,000 |
| Net Borrowing | -5.00M |
| Free Cash Flow | -88.09M |
| FCF Per Share | -$1.92 |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,026.28% |
| Pretax Margin | -912.25% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioAge Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -43.29% |
| Shareholder Yield | -43.29% |
| Earnings Yield | -45.51% |
| FCF Yield | -34.71% |
Analyst Forecast
The average price target for BioAge Labs is $32.56, which is 524.95% higher than the current price. The consensus rating is "Buy".
| Price Target | $32.56 |
| Price Target Difference | 524.95% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | -32.14% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioAge Labs has an Altman Z-Score of 12.72 and a Piotroski F-Score of 4.
| Altman Z-Score | 12.72 |
| Piotroski F-Score | 4 |